

Please try another search
Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades for Alcon, Neogenomics, Enact, and Halozyme Therapeutics .InvestingPro subscribers...
Investing.com - Halozyme (NASDAQ: HALO) reported first quarter EPS of $0.47, $0.08 better than the analyst estimate of $0.39. Revenue for the quarter came in at $162.14M versus the consensus estimate...
By Davit KirakosyanInvesting.com -- Here is your daily Pro Recap of the biggest analyst cuts you may have missed on InvestingPro since yesterday. Start your free 7-day trial to get this news...
Investing.com - Halozyme (NASDAQ: HALO) reported fourth quarter EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181M versus the consensus estimate of...
Halozyme Therapeutics (NASDAQ:HALO) reported Q4 EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181 million versus the consensus estimate of...
Halozyme Therapeutics (HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review